• Hua-Hsi Wu, Peng-Hui Wang, Yi-Jen Chen, and Wei-Ting Chao.
• Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan ROC; Department of Obstetrics and Gynecology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan ROC; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan ROC.
• J Formos Med Assoc. 2024 Aug 20.

Background/PurposeThis retrospective study evaluated the efficacy and adverse effects of oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) with secondary cytoreductive surgery (CRS) in patients with recurrent ovarian cancer.MethodsPatients diagnosed with recurrent epithelial ovarian cancer, including fallopian tube and peritoneal origin, who underwent oxaliplatin-based HIPEC with secondary CRS, were enrolled. The primary outcome was progression-free survival (PFS), and the secondary outcomes were overall survival (OS) and adverse events.ResultsA total of 33 patients were included in the analysis. The mean PFS and OS were 20.4 months (95% CI 16.3-24.5 months) and 26.7 months (95% CI 23.7-29.7), respectively. Furthermore, the OS and PFS between platinum-sensitive and resistant recurrence showed no significant difference. Univariate and multivariate analysis of PFS identified a pre-operative peritoneal carcinomatosis index (PCI) score of ≥5 as a poor prognostic factor. Among them, the incidence of acute kidney injury was 9.0 % & none had grade ≧3 adverse events.ConclusionOxaliplatin-based HIPEC with secondary CRS might provide a survival benefit for patients with recurrent ovarian cancer with a decreased incidence of renal toxicity compared to cisplatin-based regimens. It might be effective and feasible in selected recurrent ovarian cancer patients, regardless of platinum-sensitive or resistant.Copyright © 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

5 keywords...

hide…